Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could yearly Low-Energy laser replace daily eye drops for glaucoma?

NCT ID NCT04967989

Disease control Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at whether a gentle laser treatment (SLT) works as well as the standard version for people with glaucoma or high eye pressure. It also tests if getting the gentle laser once a year can delay or prevent the need for daily eye drops. About 790 adults will take part to find the best way to manage the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 790 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 or older and in good health 2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes): 1. High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes) 2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page) 3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page). 3. Each eye with BCVA 20/200 (UK 6/60) or better Exclusion Criteria: 1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment) 2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure 3. Advanced POAG in either eye (worse than moderate POAG as defined above) 4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye 5. Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye 6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye 7. Contraindications to SLT or any other study intervention 8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye 9. Any intraocular surgical procedure within the past 6 months in either eye 10. Inability to attend all scheduled study visits 11. Pregnant or planning to become pregnant in the next 4 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma and ocular hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma and ocular hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chicago Arbor Eye Institute

    RECRUITING

    Orland Park, Illinois, 60467, United States

  • Clear Vue Laser Eye Center

    RECRUITING

    Lakeworth, Florida, 33467, United States

  • Cleveland Clinic Cole Eye Institute

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Devers Eye Institute

    RECRUITING

    Portland, Oregon, 97210, United States

  • Doheny Eye Center UCLA

    RECRUITING

    Pasadena, California, 91105, United States

  • Eye Care Specialists

    RECRUITING

    Kingston, Pennsylvania, 18704, United States

  • Harvard Eye Associates

    RECRUITING

    Laguna Hills, California, 92653, United States

  • Illinois Eye Center

    RECRUITING

    Peoria, Illinois, 61615, United States

  • Kresge Eye Institute Wayne State University

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Mark Latina, LLC

    RECRUITING

    Reading, Massachusetts, 01867, United States

  • Massachusetts Eye and Ear

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mile High Eye Institute

    RECRUITING

    Sheridan, Colorado, 80110, United States

  • New York Eye Surgery Associates

    RECRUITING

    The Bronx, New York, 10469, United States

  • Northwestern Medical Group

    RECRUITING

    Chicago, Illinois, 60615, United States

  • Ocular Health Centre

    ACTIVE_NOT_RECRUITING

    Kitchener, Ontario, N2A0K5, Canada

  • Ophthalmic Consultants of Boston

    RECRUITING

    Boston, Massachusetts, 02451, United States

  • Ophthalmology Associates

    RECRUITING

    Fort Worth, Texas, 76102, United States

  • Scheie Eye Institute

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Spokane Eye Clinical Research

    RECRUITING

    Spokane, Washington, 99204, United States

  • UPMC Eye Center

    ACTIVE_NOT_RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • University Hospitals Eye Institute

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of California, Davis

    RECRUITING

    Sacramento, California, 95817, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Michigan Kellogg Eye Center

    RECRUITING

    Ann Arbor, Michigan, 48105, United States

  • University of Wisconsin-Madison

    RECRUITING

    Madison, Wisconsin, 53705, United States

  • Vanderbilt Eye Institute

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • West Virginia University

    RECRUITING

    Morgantown, West Virginia, 26505, United States

  • Wills Eye Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Wilmer Eye Institute Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.